Here are the DEF 14A proxy statements from Travere Therapeutics, Inc. (TVTX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVTX filings page.
Travere Therapeutics, Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 19, 2026 at the company’s San Diego headquarters. Stockholders of record at the close of business on March 23, 2026, when 92,369,812 common shares were outstanding, may vote.
Key items include electing ten directors for one-year terms, approving an amendment to the 2018 Equity Incentive Plan to add 3,000,000 shares for equity awards, advisory approval of executive compensation and the preferred frequency of say‑on‑pay votes, and ratification of Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
The proxy also details board independence, committee responsibilities, board risk oversight (including cybersecurity and ESG), and significant stockholder and management ownership levels, such as several institutions each holding more than 5% of outstanding shares as of March 2, 2026.